Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 10/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 3/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2493050 | 1.00 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2410408 | 1.00 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2411105 | 1.00 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2408735 | 1.00 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2408732 | 1.00 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2408835 | 0.94 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2408838 | 0.94 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2409496 | 0.94 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2414167 | 0.94 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 | |
| SCHEMBL2416443 | 0.94 | GSR (0.44) | GSRCA2MAPTBCHECHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2369924-B1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| EP-2369924-B1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8530521-B2 | Nitrooxy cycloalkane derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530521-B2 | Nitrooxy cycloalkane derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530521-B2 | Nitrooxy cycloalkane derivatives | MERCK SHARP & DOHME CORP. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME LLC | 2011-09-22 | — | — | US | disclosed |
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME LLC | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | AGTR2, AGTR1, NR3C2 | GSR 761/4885CA2 213/4885MAPT 3838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.